Bristol's $1 billion Bavarian deal may signal cancer vaccine revival

March 4, 2015 3:45 PM

6 0

LONDON (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.

The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page